Optimization of therapy in a patient with coronary heart disease in clinical practice: proven efficacy of the selective If channel inhibitor ivabradine

封面

如何引用文章

全文:

详细

The paper describes a clinical case of developing coronary heart disease in a young man, by analyzing the specific features of the disease and performed therapy. It discusses the management of this man according to the current recommendations and evidence-based medicine. The paper gives evidence for the importance of controlling heart rate in patients with angina pectoris. The most rational combinations of anti-ischemic agents for clinical application are discussed. Particular emphasis is laid on the selective If channel inhibitor ivabradine and its clinical effects: its good antianginal activity and ability to reduce the risk of cardiovascular events.

作者简介

M. Bubnova

State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation, Moscow

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лабораторией профилактики атеросклероза и тромбоза ФГБУ ГНИЦ ПМ

参考

  1. Fihn S.D., Gardin J.M., Abrams J et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. JACC 2012; 60 (24): e44–164.
  2. Бокерия Л.А., Гудкова Р.Г. Сердечно - сосудистая хирургия. М.: Изд - во НЦССХ им. А.Н.Бакулева РАМН, 2010.
  3. Бубнова М.Г., Аронов Д.М., Оганов Р.Г. и др. Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование «ПЕРСПЕКТИВА» (часть I). Кардиоваскуляр. терапия и профилактика. 2010; 6: 47–56.
  4. Ипатов П.В., Кротов А.В., Бойцов С.А. Первая помощь при неотложных состояниях с использованием карманных аптечек. Медицина неотложных состояний. 2009; 3–4: 22–3.
  5. Гафаров В.В., Благинина М.Ю. Смертность от острого инфаркта миокарда (эпидемиологическое исследование на основе программ ВОЗ «Регистр острого инфаркта миокарда, МОНИКА»). Кардиология. 2005; 5: 49–51.
  6. Аронов Д.М. Коронарная недостаточность у молодых. М.: Медицина, 1974.
  7. Карпов Ю.А., Сорокин Е.В. Стабильная ишемическая болезнь сердца. Медицинское информационное агентство. 3-е изд. М., 2012; с. 208–12.
  8. Dahlen G.H., Guyton J.R., Attar M et al. Association of levels of lipoprotein (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758–65.
  9. Assman G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle - aged men. Am J Cardiol 1996; 77: 1179–84.
  10. Dahlen G.H. Lp(a) lipoprotein in cardiovascular disease. Review and new point. Atherosclerosis 1994; 108: 111–26.
  11. Steg Ph.G., James S.K., Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J; doi: 10.1093/eurheart/ehs215.
  12. Заключение Совета экспертов российских обществ. Оптимизация терапии статинами пациентов высокого и очень высокого сердечно - сосудистого риска. CardioCоматика 2011; 4: 87.
  13. Fox K, Garcia M.A.A., Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1334–81.
  14. Patel S.R., Breall J.A., Diver D.J., Levy A.P. Bradycardia is associated with development of coronary collateral vessels in humans. Coron Artery Dis 2000; 11: 467–71.
  15. Pratt C.M., Mc Mahon R.P., Goldstein S et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia [the Asymptomatic Cardiac Ischemia Pilot (ACIP) study]. Am J Cardiol 1996; 77: 1302–9.
  16. Kolloch R, Legler U.F., Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease findings from the International VErapamil-SR/trandalopril Study (INVEST). Eur Heart J 2008; 29: 1327–34.
  17. Fox K, Ford L, Steg P.G. et al. On behalf of the BEAUTIFUL Investigators. Heart rate a prognostic risk factor in patients with coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized, controlled trial. Lancet 2008; doi: 10.1016/S-140-6736(08)61171-X.
  18. Шальнова С.А., Деев А.Д., Оганов Р.Г. Частота пульса и смертность от сердечно - сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология. 2005; 10: 45–50.
  19. Persky A, Olsson G, Laudou C et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992; 123: 606–16.
  20. Heidland U.E., Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104 (13): 1477–82.
  21. Beere P, Glagov S, Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180–2.
  22. Сustodis F, Baumhaekel M, Schlimmer N et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008; 117: 2377–87.
  23. Hjalmarson A, Gilpin E, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infection. Am J Cardiol 1990; 65: 547–53.
  24. Zuanetti G, Hernandez-Bernal F, Rossi A et al. Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction the GISSI experience. Eur Heart J 1999; 1 (Suppl. H): H52–H57.
  25. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post - myocardial infarction: a meta - regression of randomized clinical trials. Eur Heart J 2007; 28: 3012–9.
  26. Parodi G, Bellandi B, Valenti R et al. Heart rate as an independent prognostic risk factor in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Atherosclerosis 2010; 211: 255–9.
  27. Fox K, Ford L, Steg P.G. et al. On behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a randomized, double - blind, placebo - controlled trial. Lancet 2008; 37: 807–16.
  28. Colin P, Ghaleh B, Monnet X et al. Contributions of heart and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003; 284: H676–H682.
  29. Simon L, Gheleh B, Puybasset L et al. Coronary and hemodynamic effects of S 16257, a new bradycardiac agent, in resting and exercising conscious dog. J Pharmacol Exp Ther 1995; 275: 659–66.
  30. Vilaine J.P., Thollon C, Villeneuve N et al. Procoralan, a new selective If current inhibitor. Eur Heart J 2003; 5 (Suppl. G): G26–35.
  31. Tardif J.C., Ford I, Tendera M, Bourassa M.G. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with stable angina. Eur Heart J 2005; 26: 2529–36.
  32. Ruzyllo W, Ford I, Tendera M et al. Antianginal and anti - ischemic effects of ivabradine compared to amlodipine in patients with stable effort angina: a 3-month randomized, double - blind,, multicentre, noninferiority trial. Drugs 2007; 67: 393–405.
  33. Tendera M, Bores J, Tardif J.C. Efficacy of If Inhibition with Ivabradine in Different Subpopulations with Stable Angina Pectoris. Cardiology 2009; 114: 116–25.
  34. Fox K, Ford L, Steg P.G. et al. On behalf of the BEAUTIFUL Investigators. Relationship between ivabradine and cardiovascular outcomes in patients with stable coronary artery disease and left - ventricular systolic dysfunction with limiting angina: a subgroup analysis of a randomized, controlled BEAUTIFUL trial. Eur Heart J; doi: 10.1093/eurheart/ehp358.
  35. Tardif J.C., Berry C. From coronary artery disease to heart failure: potential benefits of ivabradine. Eur Heart J 2006; 8 (Suppl. D): D24–D29.
  36. Fox K.M., Mulcahy D, Findlay I et al. TIBET Study Group The Total Ischaemic Burden European Trial (TIBET): effects of atenolol, nifedipine SR, and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996; 17: 96–103.
  37. Savonitto S, Ardission D, Egstrup K et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of international multicenter angina exercise (IMAGE) study. J Am Coll Cardiol 1996; 27: 311–6.
  38. Klein W.W., Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris. Coron Artery Dis 2002; 13: 427–36.
  39. Knight C, Fox K.M. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Study in Angina Research (CESAR) Investigators. Am J Cardiol 1998; 81: 133–6.
  40. Pehrsson S.K., Ringqvist I, Ekdahl S et al. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clin Cardiol 2000; 23: 763–70.
  41. Tardif J.,. Ponikowski P, Kahan T. For the ASSOCIATE. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta - bloker therapy: a 4-month, randomized, placebo - controlled trial. Eur Heart J 2009; 30: 440–8.
  42. Глезер М.Г., Сайгитов Р.Т. от имени участников исследования КОНТРОЛЬ. Антиангинальная эффективнсть и переносимость ивабрадина в терапии пациентов со стабильной стенокардией: результаты исследования КОНТРОЛЬ (Кораксан в комбинированной терапии с бета - адреноблокаторами у пациентов со стабильной стенокардией. Антиангинальная эффективность и переносимость). Кардиология. 2010; 11: 65–75.

版权所有 © Eco-Vector, 2013

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

##common.cookie##